

March 24, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer
(Securities Code: 4582)

Notice of Appointments of Board Directors, a Substitute Member of the Audit & Supervisory Committee, and Appointments of Corporate Officers

TOKYO, Japan, March 24, 2026 - SymBio Pharmaceuticals Limited (Headquarters: Tokyo) today announced the appointments of its Board Directors (excluding directors who are Audit & Supervisory Committee Members), Board Directors who are Audit & Supervisory Committee Members, and one Substitute Board Director who is an Audit & Supervisory Committee Member. These appointments were approved at the 21st Annual General Meeting of Shareholders (the “AGM”) held today. Furthermore, the appointments of the Representative Director and Corporate Officers were resolved at the Board of Directors meeting convened following the conclusion of the AGM. The details of the appointments are as follows:

- Board Directors (excluding directors who are Audit and Supervisory Committee members) (Of the five Board Directors who are not members of Audit & Supervisory Committee, one is newly appointed.)

Name	Title
Fuminori Yoshida	Representative Director
Hiroshi Nomura (newly appointed)	Board Director <Outside>
Bruce David Cheson	Board Director <Outside>
George Morstyn	Board Director <Outside>
Ralph Smalling	Board Director <Outside>

- Board Director who is a member of Audit & Supervisory Committee (Of the three Board Directors who are members of Audit & Supervisory Committee, two are newly appointed.)

Name	Title
Koichi Shimomura	Board Director, Full-Time Audit & Supervisory Committee Member <Outside>
Eiji Mizutani (newly appointed)	Board Director, Audit & Supervisory Committee Member <Outside>

Tsuyoshi Ichinosawa (newly appointed)	Board Director, Audit & Supervisory Committee Member <Outside>
--	---

3. Substitute Board Director who is a member of the Audit & Supervisory Committee

Name	Title
Kesao Endo (newly appointed)	Substitute Board Director, Audit & Supervisory Committee Member <Outside>

4. Corporate Officers

Name	Title
Fuminori Yoshida	President and Chief Executive Officer
Edwin Rock	Corporate Vice President and Head of Global R&D Division
Paul Marston	Managing Corporate Officer and General Counsel
Takeo Okuno	Corporate Officer and Chief Financial Officer
Minori Rosales	Corporate Officer, CMO Oncology and Head of Japan Development Division

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125